Illumina, Inc. $ILMN Stock Holdings Decreased by Triple Frond Partners LLC

Triple Frond Partners LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 374,160 shares of the life sciences company’s stock after selling 16,440 shares during the quarter. Illumina makes up approximately 5.1% of Triple Frond Partners LLC’s holdings, making the stock its 8th largest position. Triple Frond Partners LLC’s holdings in Illumina were worth $49,075,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Capital World Investors increased its holdings in Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp increased its holdings in Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after buying an additional 382,520 shares during the last quarter. AQR Capital Management LLC increased its holdings in Illumina by 3.1% in the third quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock valued at $315,915,000 after buying an additional 102,147 shares during the last quarter. Geode Capital Management LLC increased its holdings in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in Illumina by 5.5% in the fourth quarter. Primecap Management Co. CA now owns 1,989,679 shares of the life sciences company’s stock valued at $260,966,000 after buying an additional 104,400 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,003,154 shares of company stock valued at $155,600,208. Corporate insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ILMN shares. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Royal Bank Of Canada started coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Citigroup increased their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Guggenheim increased their target price on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday, June 1st. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $142.13.

Illumina Stock Performance

Shares of ILMN stock opened at $160.97 on Friday. The stock’s 50-day moving average is $141.65 and its two-hundred day moving average is $134.99. The firm has a market cap of $24.35 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 3.11 and a beta of 1.50. Illumina, Inc. has a 1 year low of $85.77 and a 1 year high of $177.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.